SensoDetect AB: SensoDetect aims to capture 10% of a €6.8 Billion ASD and ADHD Diagnostics Market
"We're revolutionizing neurodiagnostics," declares PA Hedin, CEO of SensoDetect AB. "Our breakthrough SensoDetect Diagnostics (SDD) system will transform the current 6-18-month diagnostic process into a 30-minute clinical procedure, including world-first newborn screening capabilities. In a market serving 78 million undiagnosed cases, we're uniquely positioned to drive both clinical impact and strong returns."
Market Opportunity
- €6.8B global ASD/ADHD diagnostics market
- 1 in 36 children affected by ASD (CDC 2023)
- Critical need for early intervention (before age 3)
Proven Solution
Objective ABR+AI analysis
Mass screening capability
Already deployed in Middle East clinics
Revenue Drivers
- Hardware: €2K-€50K/unit
- Testing: €300/assessment (80% margins)
- Telemedicine: €200/month subscriptions
Growth Catalysts
- 2025: Saudi commercialization
- 2025: China NMPA approval
- 2026: China commercialization
- 2027: US expansion
"What sets us apart," continues CEO Hedin, "is our ability to turn this healthcare crisis into a €6.8 Billion market opportunity while delivering life-changing screening and diagnostics. We're not just participating in the neurodiagnostic space - we're redefining it," emphasizes CEO Hedin. "With secured regulatory approvals and clear regulatory pathways, we're targeting 10% market share by 2030."
Data verified via [CDC](https://www.cdc.gov) | [SEC](https://www.sec.gov) | [SFDA](https://www.sfda.gov.sa)